Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



CV Therapeutics Expands Ranexa's Reach

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

By most measures, it's been a good year for specialty drug developer CV Therapeutics (Nasdaq: CVTX  ) . That year recently got a little better, after CVT announced that it had finally found a European marketing partner for its angina treatment Ranexa.

Ranexa is CVT's top drug, approved for marketing in the U.S. since 2006. In early July, CVT finally also received final marketing approval for Ranexa in the European Union. But it hasn't launched the drug over there yet because of the costs involved, hoping instead to pair up with a larger partner first.

Late last week, CVT finally got its Ranexa partnership deal with the privately held Menarini Group. The deal gives CVT $70 million in up-front cash, as much as $315 million in milestone payments for further commercialization and development, and a "very significant double-digit royalty" rate on all sales of Ranexa by the Menarini Group in Europe and several other locales around the world.

As CVT noted on its conference call, the Menarini Group has one of the largest presences in cardiovascular drug sales in Europe. The 9 million cardiovascular drug sales calls it makes in a year dwarf the 6.5 million made by its nearest competitor, Novartis (NYSE: NVS  ) .

Why does finding a large, well-funded partner like the Menarini Group matter for CVT? Angina is a chronic condition, and as many as 50 million angina prescriptions are written each year in the five largest European countries alone. With several generic drugs on the market making angina a relatively low-margin indication, and a large angina patient population, a drugmaker needs lots of resources just to field a sales force to launch a compound like Ranexa. The Menarini Group already has such a sales force in place, plus experience in selling compounds for several firms, including Pfizer's (NYSE: PFE  ) Lipitor, GlaxoSmithKline's (NYSE: GSK  ) asthma medicine Advair, and Merk's (NYSE: MRK  ) type 2 diabetes drug Januvia.

On the conference call, CVT said that it thought Ranexa could eventually become a "blockbuster" drug in Europe, with sales of at least $1 billion annually. If so, CVT could eventually bring in more than $100 million to $200 million in royalty revenue from the Menarini Group's Ranexa sales. Considering the company had revenue of $117 million over the last four quarters, that's significant.

Ranexa is not expected to launch in Europe until the first quarter of 2009, so we'll have to wait for the actual sales figures to start rolling in. It's never smart to take any drugmaker's potentially pie-in-the-sky sales projections at face value. But if Ranexa can become anything close to a blockbuster drug in Europe, CVT's shares are undervalued at current levels.

CV Therapeutics is an active pick of our market-beating Rule Breakers newsletter. You can check out all our other recommendations, and get access to our message boards and exclusive content, with a 30-day free trial.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. Pfizer is both an Inside Value and an Income Investor pick. Glaxo was also chosen by Income Investor. The Fool has an A+ disclosure policy.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 17, 2008, at 7:48 PM, bilysquier wrote:

    If this drug does 1B in sales in Europe, it could net more than 100-200M for that year to CVTX. The royalty rate could well be more than 20% and it is at least 20% - the CEO laid that out in the conference call by saying that the rate is higher than anything else they have a royalty on. The highest they have now is Regadenoson, at 20%. Other experts have asserted that the royalty rate is 30%. So, instead you should have wrote 200-300M to CVTX.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 730206, ~/Articles/ArticleHandler.aspx, 10/21/2016 5:34:50 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 8 hours ago Sponsored by:
DOW 18,162.35 -40.27 -0.22%
S&P 500 2,141.34 -2.95 -0.14%
NASD 5,241.83 -4.58 -0.09%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/17/2009 4:00 PM
CVTX.DL $20.01 Down +0.00 +0.00%
CV Therapeutics CAPS Rating: **
GSK $41.43 Down -0.06 -0.14%
GlaxoSmithKline CAPS Rating: ***
MRK $61.92 Up +0.05 +0.08%
Merck and Co. CAPS Rating: ****
NVS $75.92 Up +0.27 +0.36%
Novartis CAPS Rating: ****
PFE $32.54 Down -0.06 -0.18%
Pfizer CAPS Rating: ****